It is the first GLP-1RA developed for oral administration, and it comprises a co-formulation of the peptide semaglutide with the absorption enhancer sodium N -(8-[2-hydroxybenzoyl] amino) caprylate, which overcomes the challenges of peptide absorption in the acidic conditions of the stomach
Start your intake Medications That Reduce GLP-1 Efficacy Through Gastric Mechanisms Anticholinergic drugsincluding certain antihistamines, antispasmodics, and some antidepressantsslow gastric motility, potentially reducing GLP-1 absorption and effectiveness
Micro- and Nanocarriers for Oral Delivery of GLP-1 and Its Analogs As reported in the referenced studies [200,201,202,203], the oral relative bioavailability of pure liraglutide and exenatide is nearly 0%, which highlights the importance of an effective drug delivery system
Long-Term Effects After 20 weeks, the results of semaglutide are fully realized